+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Epigenetics Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4591850
  • Report
  • June 2020
  • Region: Europe
  • 71 pages
  • Mordor Intelligence
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Diagenode Inc.
  • Epitherapeutics
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Merck & Co.
  • Qiagen
  • MORE
The European epigenetics market is expected to register a CAGR of nearly 14.5% over the forecast period. Factors that are responsible for the growth of this market include the increasing incidence and prevalence of cancer, the increasing funding for R&D in healthcare, and rising epigenetic applications in non-oncology diseases.

The epigenetics market is increasing in the European region. For instance, according to WHO, more than 3.7 million new cases of cancer and 1.9 million deaths occur due to cancer every year, and cancer represents the second most important cause of death and morbidity in the European region. Epigenetics is used in the study of changes in gene expression, which are useful in cancer diagnosis. This depicts the large pool of cancer patients, which will propel the growth of the epigenetics market. So, with the increasing cancer prevalence, the market is expected to grow. However, factors, such as the rising cost of instruments are expected to restrain the growth of the market.

Key Market Trends

Oncology is Expected to Grow Faster in the Application Segment

In the last few years, the market has been a golden age for cancer genetics. The cost of gene sequencing has dropped low enough for researchers to read the genomes of many thousands of patients, comparing the DNA of the diseased and healthy tissues to find the mutations associated with tumor formation and growth, which is associated with cancer. The epigenetic innovations are unobtrusively crafting a toolbox for the powerful drugs to treat cancer. And the rising prevalence of cancer in the European region is expected to drive the oncology application in the European epigenetic market.

Competitive Landscape

The European epigenetic market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. . Some of the major players of the market are Merck & Co., Qiagen, Roche, Thermo Fisher Scientific, and Illumina Inc., among others.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Diagenode Inc.
  • Epitherapeutics
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Merck & Co.
  • Qiagen
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence and Prevalence of Cancer
4.2.2 Increasing Funding for R&D in Healthcare
4.2.3 Rising Epigenetic Applications in Non-Oncology Diseases
4.3 Market Restraints
4.3.1 Rising Cost of Instruments
4.3.2 Dearth of Skilled Researchers
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Product
5.1.1 By Kits
5.1.1.1 Bisulfite Conversion Kits
5.1.1.2 Chip-seq Kits
5.1.1.3 RNA Sequencing Market
5.1.1.4 Whole Genome Amplification Market
5.1.1.5 5-HMC and 5-MC Analysis Kits
5.1.1.6 Other Kits
5.1.2 By Reagents
5.1.2.1 Antibodies
5.1.2.2 Buffers
5.1.2.3 Histones
5.1.2.4 Magnetic Beads
5.1.2.5 Primers
5.1.2.6 Other Reagents
5.1.3 By Enzymes
5.1.3.1 DNA - Modifying Enzymes
5.1.3.2 Protein Modifying Enzymes
5.1.3.3 RNA Modifying Enzymes
5.1.4 By Instruments
5.1.4.1 Mass Spectrometer
5.1.4.2 Sonicators
5.1.4.3 Next Generation Sequencers
5.1.4.4 Other Instruments
5.2 By Application
5.2.1 Oncology
5.2.2 Non-Oncology
5.2.2.1 Inflammatory Diseases
5.2.2.2 Metabolic Diseases
5.2.2.3 Infectious Diseases
5.2.2.4 Cardiovascular Diseases
5.2.2.5 Other Non-Oncology Applications
5.2.3 Developmental Biology
5.2.4 Other Research Areas
5.3 By Technology
5.3.1 DNA Methylation
5.3.2 Histone Methylation
5.3.3 Histone Acetylation
5.3.4 Large noncoding RNA
5.3.5 MicroRNA modification
5.3.6 Chromatin Structures
5.4 Geography
5.4.1 Europe
5.4.1.1 Germany
5.4.1.2 UK
5.4.1.3 France
5.4.1.4 Italy
5.4.1.5 Spain
5.4.1.6 Rest of Europe

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Diagenode Inc.
6.1.2 Epitherapeutics
6.1.3 Illumina, Inc.
6.1.4 Merck & Co.
6.1.5 Qiagen
6.1.6 F. Hoffmann-La Roche AG
6.1.7 Thermo Fisher Scientific
6.1.8 Zymo Research Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Diagenode Inc.
  • Epitherapeutics
  • Illumina, Inc.
  • Merck & Co.
  • Qiagen
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific
  • Zymo Research Corporation
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll